Bifogade filer
Kurs
-0,73%
Likviditet
0,36 MSEK
Prenumeration
Kalender
Tid* | ||
2025-11-13 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-22 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-06 | N/A | Årsstämma |
2025-05-06 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-02-13 | 08:00 | Bokslutskommuniké 2024 |
2024-11-08 | - | Kvartalsrapport 2024-Q3 |
2024-08-23 | - | Kvartalsrapport 2024-Q2 |
2024-06-03 | - | Split IMMU 20:1 |
2024-05-20 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2024-05-17 | - | Årsstämma |
2024-05-17 | - | Kvartalsrapport 2024-Q1 |
2024-02-14 | - | Bokslutskommuniké 2023 |
2023-12-13 | - | Extra Bolagsstämma 2023 |
2023-11-09 | - | Kvartalsrapport 2023-Q3 |
2023-08-29 | - | Kvartalsrapport 2023-Q2 |
2023-05-15 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2023-05-12 | - | Årsstämma |
2023-05-12 | - | Kvartalsrapport 2023-Q1 |
2023-02-17 | - | Bokslutskommuniké 2022 |
2022-11-18 | - | Extra Bolagsstämma 2022 |
2022-11-11 | - | Kvartalsrapport 2022-Q3 |
2022-08-26 | - | Kvartalsrapport 2022-Q2 |
2022-05-11 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2022-05-10 | - | Årsstämma |
2022-05-10 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-10-28 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-05 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2021-05-04 | - | Årsstämma |
2021-05-04 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2021-01-22 | - | Extra Bolagsstämma 2021 |
2020-12-18 | - | Extra Bolagsstämma 2020 |
2020-11-05 | - | Kvartalsrapport 2020-Q3 |
2020-08-27 | - | Kvartalsrapport 2020-Q2 |
2020-04-29 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2020-04-28 | - | Årsstämma |
2020-04-28 | - | Kvartalsrapport 2020-Q1 |
2020-02-18 | - | Bokslutskommuniké 2019 |
2019-11-06 | - | Kvartalsrapport 2019-Q3 |
2019-08-20 | - | Kvartalsrapport 2019-Q2 |
2019-04-26 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2019-04-25 | - | Årsstämma |
2019-04-25 | - | Kvartalsrapport 2019-Q1 |
2019-02-15 | - | Bokslutskommuniké 2018 |
2018-11-07 | - | Kvartalsrapport 2018-Q3 |
2018-08-17 | - | Kvartalsrapport 2018-Q2 |
2018-05-04 | - | Kvartalsrapport 2018-Q1 |
2018-04-26 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2018-04-25 | - | Årsstämma |
2018-02-16 | - | Bokslutskommuniké 2017 |
2017-12-04 | - | Extra Bolagsstämma 2017 |
2017-11-17 | - | Kvartalsrapport 2017-Q3 |
2017-08-18 | - | Kvartalsrapport 2017-Q2 |
2017-05-19 | - | Kvartalsrapport 2017-Q1 |
2017-04-27 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2017-04-26 | - | Årsstämma |
2017-02-17 | - | Bokslutskommuniké 2016 |
2016-05-20 | - | Kvartalsrapport 2016-Q3 |
2016-02-19 | - | Kvartalsrapport 2016-Q2 |
2015-12-03 | - | Årsstämma |
2015-09-18 | - | Bokslutskommuniké 2015 |
2015-05-21 | - | Kvartalsrapport 2015-Q3 |
2015-02-20 | - | Kvartalsrapport 2015-Q2 |
2014-12-04 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2014-12-03 | - | Årsstämma |
2014-11-18 | - | Kvartalsrapport 2015-Q1 |
2014-09-17 | - | Bokslutskommuniké 2014 |
2014-05-07 | - | Kvartalsrapport 2014-Q3 |
2014-02-18 | - | Kvartalsrapport 2014-Q2 |
2013-12-04 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
2013-12-03 | - | Årsstämma |
2013-12-03 | - | Kvartalsrapport 2014-Q1 |
2013-09-10 | - | Bokslutskommuniké 2013 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Press release
Stockholm, Sweden, January 8, 2024
Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming industry conferences:
Executive Insights 2024
Stockholm, Sweden, April 9, 2024
CEO Erik Manting will participate in the annual Executive Insights Forum: Drugs and Money in a Time of Change. Executive Insights is a networking event for Swedish executives and investors.
https://executive-insights-2024.confetti.events/
Investing in Oncology Forum
Stockholm, Sweden, April 10, 2024
CEO Erik Manting will present and take part in a panel discussion at the Investing in Oncology Forum 2024 hosted by Cord Communications.
https://financialhearings.com/event/49788
EBMT 2024
Glasgow, Scotland, April 14-17, 2024
CMO Jeroen Rovers will participate in the 50th annual meeting of EBMT, a non-profit medical and scientific organization connecting patients, researchers and other stakeholders to anticipate the future of cellular and stem cell-based therapies.
https://www.ebmt.org/annual-meeting-2024
Van Lanschot Kempen Life Sciences Conference
Amsterdam, The Netherlands, April 16-17, 2024
Mendus management will participate in the annual Van Lanschot Kempen Life Sciences investor conference.
https://www.vanlanschotkempen.com/en-nl/investment-banking/equities/life-sciences-and-healthcare/life-sciences-conference-2024
LSX World Congress 2024
London, April 29-30, 2024
CEO Erik Manting will present and take part in a discussion panel at the 10th annual LSX World Congress which will take place in London.
https://informaconnect.com/lsx-world-congress/biotech-leaders/
For more information, please contact:
Erik Manting, CEO
E-mail: ir@mendus.com
About Mendus AB (publ)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/
Attachments
240408 Mendus Conferences Apr ENG